

CART-related Neurotoxicity (NT) - Epidemiology Forecast to 2032

https://marketpublishers.com/r/CD2EB35ACCA5EN.html

Date: January 2022 Pages: 60 Price: US\$ 3,950.00 (Single User License) ID: CD2EB35ACCA5EN

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'CART-related Neurotoxicity (NT) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted CART-related Neurotoxicity (NT) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

CART-related Neurotoxicity (NT) Understanding

The DelveInsight CART-related Neurotoxicity (NT) epidemiology report gives a thorough understanding of the CART-related Neurotoxicity (NT) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for CART-related Neurotoxicity (NT) in the US, Europe, and Japan. The report covers the detailed information of the CART-related Neurotoxicity (NT) epidemiology scenario in seven major countries (US, EU5,



and Japan).

CART-related Neurotoxicity (NT) Epidemiology Perspective by DelveInsight

The CART-related Neurotoxicity (NT) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The CART-related Neurotoxicity (NT) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The CART-related Neurotoxicity (NT) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

CART-related Neurotoxicity (NT) Detailed Epidemiology Segmentation

The CART-related Neurotoxicity (NT) epidemiology covered in the report provides historical as well as forecasted CART-related Neurotoxicity (NT) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight CART-related Neurotoxicity (NT) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

The CART-related Neurotoxicity (NT) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

The CART-related Neurotoxicity (NT) Epidemiology Report and Model provide an overview of the global trends of CART-related Neurotoxicity (NT) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of CART-related Neurotoxicity (NT) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan



The report helps recognize the growth opportunities in the 7MM for the patient population

The report assesses the disease risk and burden and highlights the unmet needs of CART-related Neurotoxicity (NT)

The report provides the segmentation of the CART-related Neurotoxicity (NT) epidemiology

Report Highlights

11-year Forecast of CART-related Neurotoxicity (NT) epidemiology

7MM Coverage

Prevalent and Diagnosed Cases of CART-related Neurotoxicity (NT)

Cases of CART-related Neurotoxicity (NT) by Mutation Types

CART-related Neurotoxicity (NT) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CART-related Neurotoxicity (NT)?

What are the key findings pertaining to the CART-related Neurotoxicity (NT) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?



What would be the total number of patients of CART-related Neurotoxicity (NT) across the 7MM during the forecast period (2019-2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

What is the disease risk, burden and unmet needs of CART-related Neurotoxicity (NT)?

What are the currently available treatments of CART-related Neurotoxicity (NT)?

Reasons to buy

The CART-related Neurotoxicity (NT) Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global CART-related Neurotoxicity (NT) market

Quantify patient populations in the global CART-related Neurotoxicity (NT) market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CART-related Neurotoxicity (NT) therapeutics in each of the markets covered

Understand the magnitude of CART-related Neurotoxicity (NT) population by its epidemiology

The CART-related Neurotoxicity (NT) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources



Key Assessments

Patient Segmentation

Disease Risk & Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population



Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF CART-RELATED NEUROTOXICITY (NT)

3. CART-RELATED NEUROTOXICITY (NT): DISEASE BACKGROUND AND OVERVIEW

- 3.1. Introduction
- 3.2. Sign and Symptoms
- 3.3. Pathophysiology
- 3.4. Risk Factors
- 3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

- 5.1. Epidemiology Key Findings
- 5.2. Assumptions and Rationale: 7MM
- 5.3. Epidemiology Scenario: 7MM

5.3.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in the 7MM (2019-2032)

5.4. United States Epidemiology

5.4.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in the United States (2019-2032)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in Germany (2019-2032)

5.5.2. France Epidemiology

5.5.2.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in France (2019-2032)

5.5.3. Italy Epidemiology

5.5.3.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in Italy (2019- 2032) 5.5.4. Spain Epidemiology

5.5.4.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in Spain (2019-2032)



5.5.5. United Kingdom Epidemiology

5.5.5.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in the United Kingdom (2019-2032)

5.6. Japan Epidemiology

5.6.1. CART-related Neurotoxicity (NT) Epidemiology Scenario in Japan (2019-2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

- 6.1. CART-related Neurotoxicity (NT) Treatment and Management
- 6.2. CART-related Neurotoxicity (NT) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

- 9.1. Bibliography
- 9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report



List Of Tables

LIST OF TABLES

List of Table: Table 1: CART-related Neurotoxicity (NT) Epidemiology in 7MM (2019-2032) Table 2: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in 7MM (2019-2032)Table 3: CART-related Neurotoxicity (NT) Epidemiology in the United States (2019-2032)Table 4: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in the United States (2019-2032) Table 5: CART-related Neurotoxicity (NT) Epidemiology in Germany (2019-2032) Table 6: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Germany (2019-2032)Table 7: CART-related Neurotoxicity (NT) Epidemiology in France (2019-2032) Table 8: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in France (2019-2032)Table 9: CART-related Neurotoxicity (NT) Epidemiology in Italy (2019-2032) Table 10: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Italy (2019-2032)Table 11: CART-related Neurotoxicity (NT) Epidemiology in Spain (2019-2032) Table 12: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Spain (2019-2032)Table 13: CART-related Neurotoxicity (NT) Epidemiology in the United Kingdom (2019-2032)Table 14: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in the United Kingdom (2019-2032) Table 15: CART-related Neurotoxicity (NT) Epidemiology in Japan (2019-2032) Table 16: CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Japan

(2019-2032)



List Of Figures

LIST OF FIGURES

List of Figures Figure 1 CART-related Neurotoxicity (NT) Epidemiology in 7MM (2019-2032) Figure 2 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in 7MM (2019-2032)Figure 3 CART-related Neurotoxicity (NT) Epidemiology in the United States (2019-2032)Figure 4 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in the United States (2019-2032) Figure 5 CART-related Neurotoxicity (NT) Epidemiology in Germany (2019-2032) Figure 6 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Germany (2019-2032)Figure 7 CART-related Neurotoxicity (NT) Epidemiology in France (2019-2032) Figure 8 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in France (2019-2032)Figure 9 CART-related Neurotoxicity (NT) Epidemiology in Italy (2019-2032) Figure 10 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Italy (2019-2032)Figure 11 CART-related Neurotoxicity (NT) Epidemiology in Spain (2019-2032) Figure 12 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Spain (2019-2032)Figure 13 CART-related Neurotoxicity (NT) Epidemiology in the United Kingdom (2019-2032)Figure 14 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in the United Kingdom (2019-2032) Figure 15 CART-related Neurotoxicity (NT) Epidemiology in Japan (2019-2032) Figure 16 CART-related Neurotoxicity (NT) Diagnosed and Treatable Cases in Japan (2019-2032)

*The table of contents is not exhaustive; will be provided in the final report



I would like to order

Product name: CART-related Neurotoxicity (NT) - Epidemiology Forecast to 2032 Product link: <u>https://marketpublishers.com/r/CD2EB35ACCA5EN.html</u> Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

> If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/CD2EB35ACCA5EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970